Research

The Ahmanson Translational Theranostics Division (ATTD) is a Division of the Department of Molecular and Medical Pharmacology (DMMP). The Division includes the Nuclear Medicine clinic, the Biomedical Cyclotron, as well as basic and translational research groups and labs. Fueled by the adoption of Positron Emission Tomography (PET/CT) and stimulated by major new Theranostics and therapeutic opportunities in prostate cancer and neuroendocrine tumors, the Division and Nuclear Medicine clinic has expanded significantly. Novel therapeutic approaches, together with advanced molecular imaging assays, have given rise to the field of Theranostics, the combination of tumor-specific targeted radionuclide imaging and therapy.